 |
|
|
| |
No Detectable Resistance to Bulevirtide in Participants
With Chronic Hepatitis D Through 24 Weeks of Treatment
|
| |
| |
EASL 2022 Jue 22-26 London
Julius Hollnberger,1 Yang Liu,2 Ross Martin,2 Savrina Manhas,2 Thomas Aeschbacher,2 Silvia Chang,2 Simin Xu,2 Bin Han,2 Tahmineh Yazdi,2 Lindsey May,2 Dong Han,2 Katrin Schoneweis,2 John F. Flaherty,2 Vithika Suri,2 Dmitry Manuilov,2 Roberto Mateo,2 Evguenia Svarovskaia,2 Hongmei Mo,2 Stephan Urban1
1German Center for Infection Research (DZIF) and University Hospital Heidelberg, Germany; 2Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
